Trial Profile
Open-Label Study With Rilpivirine in Treatment-naïve Indian Subjects With HIV-1 Infection to Determine Safety and Efficacy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Rilpivirine (Primary) ; Lamivudine/tenofovir-disoproxil-fumarate
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms RISE
- Sponsors Johnson & Johnson
- 19 Aug 2021 Status changed from recruiting to discontinued.
- 08 Jun 2021 Planned End Date changed from 31 May 2021 to 30 Jun 2021.
- 11 May 2021 Planned End Date changed from 30 Apr 2021 to 31 May 2021.